These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 25097944)
1. A guide to a new prostate cancer tests. Johns Hopkins Med Lett Health After 50; 2014 May; 29(3):4-5. PubMed ID: 25097944 [No Abstract] [Full Text] [Related]
2. New tests for prostate cancer. O'Hanlon LH J Natl Cancer Inst; 2013 Nov; 105(22):1672-4. PubMed ID: 24198330 [No Abstract] [Full Text] [Related]
3. Study supports PSA velocity risk count. Fillon M J Natl Cancer Inst; 2012 Jul; 104(14):1042-3. PubMed ID: 22781432 [No Abstract] [Full Text] [Related]
5. Tumour markers in monitoring the treatment of advanced prostate cancer. Cooper EH; Armitage TG Prog Clin Biol Res; 1990; 359():65-72; discussion 73-4. PubMed ID: 1704634 [No Abstract] [Full Text] [Related]
6. Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance. San Francisco IF; Werner L; Regan MM; Garnick MB; Bubley G; DeWolf WC J Urol; 2011 Feb; 185(2):471-6. PubMed ID: 21167525 [TBL] [Abstract][Full Text] [Related]
7. Measurement of prostate-specific antigen as a screening test for prostate cancer. N Engl J Med; 1991 Sep; 325(13):963-5. PubMed ID: 1715514 [No Abstract] [Full Text] [Related]
8. [Prostatic cancer--can unnecessary therapy be avoided? Prostate-specific antigens (PSA) kinetics can guide the management]. Malmström PU Lakartidningen; 2006 Feb 1-7; 103(5):279. PubMed ID: 16512565 [No Abstract] [Full Text] [Related]
9. [Specific prostatic antigen: usefulness in clinical practice]. Isa Kroon WA; Sánchez de la Muela PL; Berian Polo JM Med Clin (Barc); 1992 Mar; 98(9):345-7. PubMed ID: 1374824 [No Abstract] [Full Text] [Related]
11. Measuring the importance of PSA velocity. Tuma RS J Natl Cancer Inst; 2011 Mar; 103(6):454-61. PubMed ID: 21393606 [No Abstract] [Full Text] [Related]
12. Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators. Nam RK; Kattan MW; Chin JL; Trachtenberg J; Singal R; Rendon R; Klotz LH; Sugar L; Sherman C; Izawa J; Bell D; Stanimirovic A; Venkateswaran V; Diamandis EP; Yu C; Loblaw DA; Narod SA J Clin Oncol; 2011 Aug; 29(22):2959-64. PubMed ID: 21690464 [TBL] [Abstract][Full Text] [Related]
13. Risks of PSA screening now better understood. Peres J J Natl Cancer Inst; 2013 Nov; 105(21):1590-2. PubMed ID: 24142893 [No Abstract] [Full Text] [Related]
14. PSA screening: the USPSTF got it wrong. Scherger JE J Fam Pract; 2013 Nov; 62(11):616, 618. PubMed ID: 24288701 [No Abstract] [Full Text] [Related]
15. Researchers look to MRI and biomarkers to help improve detection of aggressive prostate cancers. Rubin R JAMA; 2015 Feb; 313(7):654-6. PubMed ID: 25629168 [No Abstract] [Full Text] [Related]
16. The redbook and prostate cancer. Brett T Aust Fam Physician; 2002 Feb; 31(2):120-1. PubMed ID: 11917820 [No Abstract] [Full Text] [Related]
17. [The specific prostatic antigen: an element of diagnostic conflict?]. Morote Robles J Med Clin (Barc); 1992 Apr; 98(15):598. PubMed ID: 1376383 [No Abstract] [Full Text] [Related]
18. [The National Board of Health and Welfare's guidelines for prostatic cancer care. PSA test screening--only for well-informed men]. Bratt O; Damber JE; Kärvinge C; Malm T; Hensjö LO; Hyttsten E Lakartidningen; 2008 Feb 20-26; 105(8):524-8. PubMed ID: 18363292 [No Abstract] [Full Text] [Related]
19. PSA screening: the bottom line. Elhilali MM CMAJ; 2000 Mar; 162(6):791-2. PubMed ID: 10750466 [No Abstract] [Full Text] [Related]
20. New test detects early prostate cancer. Health News; 2005 Sep; 11(9):9. PubMed ID: 16208809 [No Abstract] [Full Text] [Related] [Next] [New Search]